| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10013972 | HBV | ENSG00000069535.14 | protein_coding | MAOB | No | No | 4129 | P27338 |
| TVIS20025210 | HPV | ENSG00000069535.14 | protein_coding | MAOB | No | No | 4129 | P27338 |
| TVIS20068158 | HPV | ENSG00000069535.14 | protein_coding | MAOB | No | No | 4129 | P27338 |
| TVIS20064192 | HPV | ENSG00000069535.14 | protein_coding | MAOB | No | No | 4129 | P27338 |
| TVIS20020700 | HPV | ENSG00000069535.14 | protein_coding | MAOB | No | No | 4129 | P27338 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | MAOB |
|---|---|
| DrugBank ID | DB01367 |
| Drug Name | Rasagiline |
| Target ID | BE0002196 |
| UniProt ID | P27338 |
| Regulation Type | inhibitor |
| PubMed IDs | 19673610; 19499843; 12043833; 20624440; 20600573; 15573406; 20517484; 18035186; 11752352 |
| Citations | Naoi M, Maruyama W: Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Expert Rev Neurother. 2009 Aug;9(8):1233-50. doi: 10.1586/ern.09.68.@@Uzun M, Alp R, Uzlu E, Alp S, Citil M, Topcu B, Erdogan HM: Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits. Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):95-8.@@Youdim MB, Weinstock M: Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol Neurobiol. 2001 Dec;21(6):555-73.@@Chau KY, Cooper JM, Schapira AH: Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells. Neurochem Int. 2010 Nov;57(5):525-9. doi: 10.1016/j.neuint.2010.06.017. Epub 2010 Jul 17.@@Weinreb O, Amit T, Bar-Am O, Youdim MB: Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol. 2010 Nov;92(3):330-44. doi: 10.1016/j.pneurobio.2010.06.008. Epub 2010 Jun 19.@@Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T: Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res. 2005 Jan 1-15;79(1-2):172-9.@@Leegwater-Kim J, Bortan E: The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging. 2010 May 25;5:149-56.@@Chen JJ, Swope DM, Dashtipour K: Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther. 2007 Sep;29(9):1825-49.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
| Groups | Approved |
| Direct Classification | Indanes |
| SMILES | C#CCN[C@@H]1CCC2=CC=CC=C12 |
| Pathways | |
| PharmGKB | PA164764584 |
| ChEMBL | CHEMBL887 |
